25 February 2020

The cervical screening program was established to identify increased risk of cervical cancer in women aged between 30 and 60 years. Cervical cancer is caused by a long-term virus infection: the human papillomavirus (HPV). Early detection of HPV can prevent cervical cancer. The Biobank BVO contains left-over cytological material from the cervical screening program. The ambition of the BVO Biobank is to make this residual material available for scientific research to optimize the current cervical cancer screening program. Moreover, it aims to create a more personalized intervention by promoting better understanding of the oncogenic progression and transformation of high-risk HPV (hrHPV) infected cells and the identification/testing of biomarkers or biomarker profiles.
 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud biobank

Related news items


Farewell Dorine Swinkels

1 September 2026

On Friday, September 4th, 2026, Dorine Swinkels will retire as Professor of Experimental Clinical Chemistry at Radboudumc. She is also leaving the Radboud Biobank.

go to page

Greening Radboud Biobank – reduction number of aliquots in storage for future initiatives

1 September 2026

Like LUMC and NKI, the Radboud Biobank will also store fewer aliquots per collection tube.

go to page

Effect of Fit & Funding on external invoices

1 September 2026

The Radboud Biobank not only manages issuances and projects for Radboudumc but also provides external services. The Radboud Biobank invoices the external organization for these services.

go to page

New link between iLES and Castor EDC connects clinical data and biobank material

1 September 2026

The Biobank Information Management System, iLES, is now linked to Castor EDC. This development was realized within a KWF-funded project.

go to page

Radboud Biobank's 2025 annual report

3 March 2026

The Radboud Biobank's 2025 annual report is now available on request.

go to page

Aevai Health developed a virtual assistant

3 March 2026

Aevai Health has developed Alva - a virtual assistant to engage research participants, which can support participants with health literacy, understanding research protocols, and with using measurement devices.

go to page